NCT01478399View on ClinicalTrials.gov

Pharmacokinetic, Safety/Tolerability Study of a Single SC Dose of PB1023 Injection in Subjects With Normal and Impaired Renal Function

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

October 31, 2012

Study Completion Date

October 31, 2012

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

PB1023 Injection

90 mg Dose

Trial Locations (2)

37920

New Orleans Center for Clinical Research, Knoxville

55114

Prism Research, Saint Paul

Sponsors
All Listed Sponsors
lead

PhaseBio Pharmaceuticals Inc.

INDUSTRY